- Rallybio have announced the following news regarding financing, development and it’s Lead Product Candidate, RLY211. RLYB211 is a plasma-derived hyperimmune globulin in development for the prevention of FNAIT. ———————————- 19 May 2020 Rallybio Completes $145 Million Series B Financing and Announces Plans to Advance Lead Product Candidate into the Clinic in 2H 2020 — Financing ...
Due to the pandemic coronavirus – COVID-19 Naitbabies have postponed future exhibitions and conferences until further notice. We are working from home and our online Parents Support Group is still very much active. Please find links below to Government and WHO websites. and information for pregnant women and COVID-19 UK Royal College Obstetricians ...
We ‘re excited to be exhibiting at The first All Ireland Maternity and Midwifery Festival Croke Park, Dublin February 11 2020
Cambridge Rare Disease Network are hosting #RAREsummit19 which takes place on 23rd September at the Wellcome Genome Campus, Hinxton, Cambridgeshire, England. #RAREsummit19 is a 1 day event focusing on patient-centricity in rare disease progress; highlighting exemplars of patient, patient advocacy groups and carers involvement in the development of drugs, healthcare and assistive technologies. Taking place ...- READ THE LATEST EXCITING NEWS NEWS RELEASE REGARDING THE DEVELOPMENT OF NAITgam!!!!!! Statement release from Soren Weis Dahl CEO, #Prophylix AS regarding the current status of the manufacture and development of ~#NAITgam. Prophylix AS has entered into a definitive agreement with Rallybio, a U.S.-based drug development company, under which Rallybio acquires Prophylix’s orphan drug programs, ...
Primary Care and Public Health show National Exhibition Centre, Birmingham. Naitbabies hosted a stand at the two day Primary Care show held at the NEC Birmingham on 15 – 16 May. The weather was glorious and brought thousands of people to visit the show, We had an excellent 2 days with much interest being shown ...
